Stifel analyst Benjamin Burnett said the bb2121 KarMMa data reported by Bluebird Bio (BLUE) "looks approvable" and likely will lead to Bluebird having a first mover advantage in multiple myeloma. However, although he sees Bluebird as "clearly ahead of competitors," he thinks it will be tough for the stock to appreciate beyond a small rebound given there are "so many me-too programs advancing behind them," including Janssen's (JNJ) JNJ-4528, which generated "high ORR." Burnett, who keeps a Hold rating and $96 price target on Bluebird shares, added that LentiGlobin continues to look impressive in sickle cell disease, but that disease area "has become a hotbed for gene therapy/gene editing development."
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER - Krispy... To see the rest of the story go to thefly.com. See Story Here